RegulatoryJul 30, 2026, 06:08 AM
Liminatus Pharma Believes It Meets Nasdaq Equity Rule Post-Merger
AI Summary
Liminatus Pharma, Inc. believes it has stockholders' equity in excess of $2.5 million following its merger with InnocsAI LLC. The company is currently awaiting a compliance determination from The Nasdaq Stock Market LLC regarding its listing rules. While the company anticipates compliance, Nasdaq will continue to monitor its equity requirement, and failure to evidence compliance in future periodic reports could lead to delisting.
Key Highlights
- Liminatus Pharma believes it has stockholders' equity exceeding $2.5 million.
- This is a result of the previously announced merger with InnocsAI LLC.
- The company is awaiting a compliance determination from Nasdaq.
- Nasdaq will monitor ongoing compliance with the stockholders' equity requirement.
- Future delisting is possible if compliance is not evidenced in the next periodic report.
Price Impact
More from LIMN